ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases

March 14, 2014

New NCI Director Varmus “Glad To Be Back,” Says Goal Is To Control Cancer Through Science

July 16, 2010

FDA to Require Data On saline Breast, Silcone Testicular Implants

January 29, 1993

Durant Suggests Six Efforts Needed For Survival Of Clinical Research

May 30, 1986

In Brief: Most NCI Grants, Including Noncompeting And r01s, Will Take Cuts Of At Least 4 Percent; Paylines Set

January 22, 1982

National Action Plan: Steering committee Votes No Confidence In HHS Official.

August 15, 1997